SAN FRANCISCO, CA, Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, announced the successful completion of a $43 million Series A financing round. The round was led by existing investor Andreessen Horowitz.
Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, announced the successful completion of a $43 million Series A financing round. The round was led by existing investor Andreessen Horowitz, with participation from Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV, Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels and ExitFund.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
